Sugi Predict

Sugi Predict / Compounds / SCHEMBL376485

SCHEMBL376485

SCHEMBL376485

CC(C)(C)OC(=O)N1CCC[C@H](N)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ HPGD P15428 1/20 0.53
▸ EPHX1 P07099 1/20 0.47
▸ USP2 O75604 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ PREP P48147 2/20 0.44
▸ USP30 Q70CQ3 1/20 0.44
▸ RECQL P46063 1/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ BACE1 P56817 2/20 0.42
▸ CTSD P07339 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ GLS O94925 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL181566 1.00 MAPT (0.55) MAPTMEN1ALDH1A1KMT2AHPGD
SCHEMBL181567 1.00 MAPT (0.55) MAPTMEN1ALDH1A1KMT2AHPGD
Hydrochloric Acid SCHEMBL641221 0.98 MAPT (0.53) MAPTMEN1ALDH1A1KMT2AHPGD
Hydrochloric Acid SCHEMBL31057412 0.98 MAPT (0.53) MAPTMEN1ALDH1A1KMT2AHPGD
Hydrochloric Acid SCHEMBL9104390 0.98 MAPT (0.53) MAPTMEN1ALDH1A1KMT2AHPGD
Oxalic Acid SCHEMBL25269098 0.97 MEN1 (0.52) MAPTMEN1ALDH1A1KMT2AHPGD
Hydrochloric Acid SCHEMBL6039693 0.97 MAPT (0.52) MAPTMEN1ALDH1A1KMT2AHPGD
SCHEMBL1365293 0.95 HPGD (0.55) MAPTMEN1ALDH1A1KMT2AHPGD
SCHEMBL1563471 0.95 HPGD (0.55) MAPTMEN1ALDH1A1KMT2AHPGD
SCHEMBL16041868 0.95 HPGD (0.55) MAPTMEN1ALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1051 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12104106-B2 Compositions of chiral molecules and perovskite nanocrystals and methods of making the same ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) 2024-10-01 — — US claimed
CN-118185900-B Transaminase, preparation method and application thereof, and preparation method of amino-containing compound 爱斯特（成都）生物制药股份有限公司 2024-07-30 — — CN claimed
CN-118185900-A Transaminase, preparation method and application thereof, and preparation method of amino-containing compound 爱斯特（成都）生物制药股份有限公司 2024-06-14 — — CN claimed
US-20220326082-A1 CHIRAL HETEROSTRUCTURES Alliance for Energy Innovation, LLC 2022-10-13 — — US claimed
CN-111647634-A Method for asymmetric synthesis of (S) -1-Boc-3-aminopiperidine by continuous flow of packed bed 华东理工大学 2020-09-11 — — CN claimed
CN-108975292-A A kind of preparation method of double fluorine sulfonyl imide compounds 九江天赐高新材料有限公司 2018-12-11 — — CN claimed
CN-101967141-A Method for preparing Chk protein kinase antagonist AZD-7762 SYN THESIS SHANGHAI CO LTD 2011-02-09 — — CN claimed
US-12637453-B2 Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-26 — — US disclosed
EP-4739668-A1 1,3-ISOINDOLINEDIONE DERIVATIVES AND HETEROAROMATIC ANALOGUES FOR STIMULATING ENDOTHELIAL CELL-PERICYTE INTERACTION Academisch Ziekenhuis Leiden (h.o.d.n. LUMC) (NL) 2026-05-13 — — EP disclosed
EP-4739683-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
US-12624023-B2 Sulfonylurea derivatives and uses thereof NodThera Limited (GB) 2026-05-12 — — US disclosed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
EP-4073062-B1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) RYVU THERAPEUTICS S A (PL) 2026-04-29 — — EP disclosed
EP-1501514-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2005-02-02 — — EP disclosed
WO-2005000305-A1 3-AMINOPIPERIDINES AND 3-AMINOQUINUCLIDINES AS INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2005-01-06 — — WO disclosed
US-20040224978-A1 CCR8 inhibitors MILLENNIUM PHARMACEUTICALS, INC. 2004-11-11 — — US disclosed
US-20040209948-A1 CCR8 Inhibitors MILLENNIUM PHARMACEUTICALS, INC. 2004-10-21 — — US disclosed
WO-2004058709-A1 CCR8 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2004-07-15 — — WO disclosed
WO-2004058736-A1 CCR8 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2004-07-15 — — WO disclosed
WO-2003093297-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2003-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209948-A1 CCR8 Inhibitors CCR8, CCR1, CCR3 MAPT 3918/4885MEN1 4186/4885ALDH1A1 498/4885
US-20040224978-A1 CCR8 inhibitors CCR8, CCR1, CCRL2 MAPT 2036/4885MEN1 3701/4885ALDH1A1 491/4885
US-12624023-B2 Sulfonylurea derivatives and uses thereof PYCARD, NOD1, NLRP3 MAPT 4223/4885MEN1 957/4885ALDH1A1 561/4885
US-12637453-B2 Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof MAP3K1, MAP3K3, MAPK1 MAPT 866/4885MEN1 3447/4885ALDH1A1 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.